Expert Interview
A Second Look: Discussing the potential of Omvoh, an interleukin-23p19 antagonist developed by Eli Lilly for the treatment of patients with moderately to severely active ulcerative colitis.
Ticker(s): LLYInstitution: PIH Health Downey Hospital
- A gastroenterologist in Downey, California and is affiliated with Kaiser Permanente Fontana and Ontario Medical Centers. He received his medical degree from Sidney Kimmel Medical College at Thomas Jefferson University and has been in practice between 11-20 years.
- Currently manages 350 NASH patients
- Very familiar with efruxifermin and its HARMONY Phase IIb trial
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
